- Home
- DQ vs APGE Comparison
DQ vs APGE Comparison
Compare DQ & APGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DQ
- APGE
- Stock Information
- Founded
- DQ 2006
- APGE 2022
- Country
- DQ China
- APGE United States
- Employees
- DQ N/A
- APGE N/A
- Industry
- DQ Semiconductors
- APGE Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- DQ Technology
- APGE Health Care
- Exchange
- DQ Nasdaq
- APGE Nasdaq
- Market Cap
- DQ 1.7B
- APGE 2.0B
- IPO Year
- DQ 2010
- APGE 2023
- Fundamental
- Price
- DQ $25.78
- APGE $38.27
- Analyst Decision
- DQ Buy
- APGE Strong Buy
- Analyst Count
- DQ 4
- APGE 5
- Target Price
- DQ $30.84
- APGE $95.40
- AVG Volume (30 Days)
- DQ 1.4M
- APGE 465.5K
- Earning Date
- DQ 10-29-2025
- APGE 11-11-2025
- Dividend Yield
- DQ N/A
- APGE N/A
- EPS Growth
- DQ N/A
- APGE N/A
- EPS
- DQ N/A
- APGE N/A
- Revenue
- DQ $592,959,000.00
- APGE N/A
- Revenue This Year
- DQ N/A
- APGE N/A
- Revenue Next Year
- DQ $69.31
- APGE N/A
- P/E Ratio
- DQ N/A
- APGE N/A
- Revenue Growth
- DQ N/A
- APGE N/A
- 52 Week Low
- DQ $12.41
- APGE $26.20
- 52 Week High
- DQ $30.85
- APGE $63.50
- Technical
- Relative Strength Index (RSI)
- DQ 53.37
- APGE 54.57
- Support Level
- DQ $25.61
- APGE $36.01
- Resistance Level
- DQ $27.94
- APGE $39.15
- Average True Range (ATR)
- DQ 1.59
- APGE 1.59
- MACD
- DQ -0.17
- APGE 0.08
- Stochastic Oscillator
- DQ 36.18
- APGE 76.48
About DQ DAQO New Energy Corp.
Daqo New Energy Corp is a polysilicon manufacturer based in China. The company manufactures and sells high-purity polysilicon to manufacturers who use it to make ingots, cells, and modules for solar power solutions. The polysilicon is packaged to meet crucible stacking, pulling, and solidification needs. All of the company's revenues come from the People's Republic of China.
About APGE Apogee Therapeutics Inc.
Apogee Therapeutics Inc is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology (I&I) indications with high unmet need. Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.